Golotimod

Golotimod

SCHEMBL726291

N[C@@H](CCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)C(=O)O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.65
MEN1 O00255 1/20 0.65
LMNA P02545 1/20 0.65
MPO P05164 1/20 0.65
MAPT P10636 1/20 0.65
TSHR P16473 1/20 0.65
BLM P54132 1/20 0.65
PMP22 Q01453 1/20 0.65
KMT2A Q03164 1/20 0.65
HIF1A Q16665 1/20 0.65
ERAP2 Q6P179 2/20 0.62
ALOX15 P16050 1/20 0.61
ACE P12821 4/20 0.61
ITGB2 P05107 4/20 0.60
ICAM1 P05362 4/20 0.60
ITGAL P20701 4/20 0.60
PPARG P37231 1/20 0.59
P2RY14 Q15391 1/20 0.59
TP53 P04637 1/20 0.59
POLB P06746 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Golotimod SCHEMBL14790029 1.00 KDM4E (0.65) KDM4EMEN1LMNAMPOMAPT
Golotimod SCHEMBL12966340 1.00 KDM4E (0.65) KDM4EMEN1LMNAMPOMAPT
Golotimod SCHEMBL727944 1.00 KDM4E (0.65) KDM4EMEN1LMNAMPOMAPT
Golotimod SCHEMBL1768729 1.00 KDM4E (0.65) KDM4EMEN1LMNAMPOMAPT
Orilotimod SCHEMBL733964 1.00 KDM4E (0.65) KDM4EMEN1LMNAMPOMAPT
Golotimod SCHEMBL12818886 1.00 KDM4E (0.65) KDM4EMEN1LMNAMPOMAPT
Golotimod SCHEMBL29622906 1.00 KDM4E (0.65) KDM4EMEN1LMNAMPOMAPT
Golotimod SCHEMBL726938 1.00 KDM4E (0.65) KDM4EMEN1LMNAMPOMAPT
Orilotimod SCHEMBL29379690 1.00 KDM4E (0.65) KDM4EMEN1LMNAMPOMAPT
SCHEMBL645413 0.93 ERAP2 (0.60) KDM4EMEN1LMNAMPOMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4666031-A1 MEASUREMENT OF AN OBJECT AT A TEMPERATURE THAT DIFFERS FROM THE REFERENCE TEMPERATURE Nokra Optische Prüftechnik und Automation GmbH (DE) 2025-12-24 EP claimed
WO-2025242856-A1 METHOD FOR DETERMINING POSES OF OBJECTS FOR A ROBOT ROBERT BOSCH GMBH (DE) 2025-11-27 WO claimed
EP-4626304-A1 MEDICAL IMAGING SYSTEM AND METHOD FOR OPERATING A MEDICAL IMAGING SYSTEM Karl Storz SE & Co. KG (DE) 2025-10-08 EP claimed
EP-4594999-A1 IMAGE PROCESSING METHOD FOR DETERMINING A PROCESS DISTURBANCE, AND IMAGE PROCESSING DEVICE Siemens Energy Global GmbH & Co. KG (DE) 2025-08-06 EP claimed
WO-2025132218-A1 MEASURING DEVICE FOR MEASURING AN ELECTRIC VARIABLE IN A CONDUCTOR, ASSEMBLY, AND METHOD SIEMENS AKTIENGESELLSCHAFT (DE) 2025-06-26 WO claimed
US-12292445-B2 Methods of selecting subjects for treatment with metabolomic modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-05-06 US claimed
WO-2025068576-A1 METHOD FOR ASCERTAINING MECHANICAL CHARACTERISTICS OF ADDITIVELY MANUFACTURED COMPONENTS TRACK3D GmbH (DE) 2025-04-03 WO claimed
WO-2025040305-A1 METHOD FOR SENSING A CURRENT ROBERT BOSCH GMBH (DE) 2025-02-27 WO claimed
WO-2025021693-A1 METHOD FOR DETECTING PARTIAL DISCHARGES IN AN ELECTRIC OPERATING MEANS, AND ELECTRIC OPERATING MEANS SIEMENS AKTIENGESELLSCHAFT (DE) 2025-01-30 WO claimed
WO-2025003126-A1 DEVICE FOR CONTINUOUS VIRUS INACTIVATION SARTORIUS STEDIM BIOTECH GMBH (DE) 2025-01-02 WO claimed
JP-4837251-B2 2011-12-14 JP claimed
EP-1814566-B1 TREATMENT OR PREVENTION OF HEMORRHAGIC VIRAL INFECTIONS WITH IMMUNOMODULATOR COMPOUNDS SCICLONE PHARMACEUTICALS INC (US) 2010-07-28 EP claimed
EP-2078525-A2 Treatment of tuberculosis using immunomodulator compounds SciClone Pharmaceuticals, Inc. (US) 2009-07-15 EP claimed
US-7173013-B2 Treatment of tuberculosis using immunomodulator compounds SCICLONE PHARMACEUTICALS, INC. (US) 2007-02-06 US claimed
EP-1420808-A4 TREATMENT OF TUBERCULOSIS USING IMMUNOMODULATOR COMPOUNDS SCICLONE PHARMACEUTICALS INC (US) 2006-06-07 EP claimed
US-20040259806-A1 Treatment of tuberculosis using immunomodulator compounds SCICLONE PHARMACEUTICALS, INC. 2004-12-23 US claimed
JP-2004537579-A 2004-12-16 JP claimed
EP-1420808-A1 TREATMENT OF TUBERCULOSIS USING IMMUNOMODULATOR COMPOUNDS Sciclone Pharmaceuticals, Inc. (US) 2004-05-26 EP claimed
WO-2003013572-A1 TREATMENT OF TUBERCULOSIS USING IMMUNOMODULATOR COMPOUNDS SCICLONE PHARMACEUTICALS, INC. (US) 2003-02-20 WO claimed
US-5744452-A IMMUNE SYSTEM DISORDERS, AIDS Wei, Edward T. (US) 1998-04-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259806-A1 Treatment of tuberculosis using immunomodulator compounds IFNG, IFNAR1, CD4 KDM4E 4329/4885MEN1 2589/4885LMNA 4275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.